What Happened

Otsuka Pharmaceutical presented interim Phase 3 data at the ERA Congress 2026, showing VOYXACT (sibeprenlimab) preserved kidney function in IgA nephropathy patients over 12 months. The drug demonstrated a mean eGFR change of +0.7 mL/min/1.73 m² compared to a decline of -4.8 mL/min/1.73 m² in the placebo group.

Who Is Affected

Adults with primary IgA nephropathy at risk for disease progression are the primary beneficiaries. Nephrologists and healthcare providers treating these patients will also be impacted by this development.

Market Impact

• VOYXACT strengthens Otsuka's position in the nephrology market.
• Early therapy adoption could shift treatment paradigms.
• Competitors may face increased pressure to demonstrate similar efficacy.

What to Watch

Monitor the ongoing Phase 3 VISIONARY trial for long-term efficacy and safety data. Additionally, track the FDA's response to Otsuka's rolling submission for a supplemental Biologics License Application (sBLA).